E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Congenital Haemophilia and Inhibitors Hemofilia Congénita e Inhibidores |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 13.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10056492 |
E.1.2 | Term | Haemophilia A with anti factor VIII |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 13.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10056494 |
E.1.2 | Term | Haemophilia B with anti factor IX |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Demostrar la eficacia de NNC 0078-0000-0007 para controlar las hemorragias agudas en pacientes con hemofilia congénita e inhibidores. To demonstrate the efficacy of NNC 0078-0000-0007in controlling acute bleeds in patients with congenital haemophilia with inhibitor |
|
E.2.2 | Secondary objectives of the trial |
To confirm the safety of NNC 0078-0000-0007 when administered for treatment of acute bleeds To evaluate the immunogenicity of NNC 0078-0000-0007 (formation of neutralising antibodies) To evaluate health economic impact of treatment with NNC 0078-0000-0007
Confirmar la seguridad de NNC 0078-0000-0007 cuando se administra para tratar hemorragias agudas. Evaluar la inmunogenicidad de NNC 0078-0000-0007 (formación de anticuerpos neutralizantes). Evaluar los efectos en la economía sanitaria del tratamiento con NNC 0078-0000-0007 |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Male patient with clinical diagnosis of congenital haemophilia A or B and inhibitors to coagulation factors VIII or IX. Minimum of five bleeds requiring haemostatic drug treatment within the previous 12 months at trial entry. 12 years of age or older.
Paciente varón con diagnóstico clínico de hemofilia A o B congénita e inhibidores de los factores VIII o IX de la coagulación. Un mínimo de cinco hemorragias que hayan precisado tratamiento con fármacos hemostáticos en los 12 meses previos a la inclusión en el ensayo. Edad igual o superior a 12 años. |
|
E.4 | Principal exclusion criteria |
Previous participation in this trial defined as withdrawal after administration of trial product. Patient has received an investigational medicinal product within 30 days prior to this trial. Congenital or acquired coagulation disorders other than haemophilia A or B. Any clinical signs or known history of arterial thrombotic events or of deep venous thrombosis or pulmonary embolism (as defined by available medical records). Platelet count < 50,000 platelets/µl (at the screening visit). ALAT > 3 times the upper normal limit (according to laboratory reference ranges). FVIII/IX Immune Tolerance Induction regimen planned to occur during the trial. Ongoing bleeding prophylaxis regimens or planned bleeding prophylaxis to occur during the trial. HIV positive with current CD4+ count < 200/mL (defined by medical records.
Participación previa en este ensayo, definida como retirada tras la administración de producto del ensayo. El paciente ha recibido un medicamento en investigación en los 30 días previos a este ensayo. Trastornos de la coagulación congénitos o adquiridos distintos de la hemofilia A y B congénita. Cualquier signo clínico o antecedente conocido de episodios trombóticos arteriales o trombosis venosa profunda o embolia pulmonar previas (definidos por la historia clínica disponible). Recuento de plaquetas < 50.000/µl (en la visita de selección) ALAT > 3 veces el límite superior normal (según los intervalos de referencia del laboratorio). Previsión de uso de regímenes de inducción de tolerancia inmunológica a FVIII/IX durante el ensayo. Regímenes de profilaxis de hemorragias en curso o previstos durante el ensayo. Paciente positivo para el VIH con recuento actual de CD4+ < 200/ml (definido por la historia clínica). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Effective bleeding control defined as no additional haemostatic medication (other than trial product) given within 12 hours after first dose of trial product El control eficaz de las hemorragias se define como la no administración de medicación hemostática adicional (distinta del producto del ensayo) en las 12 horas siguientes a la primera dosis de producto del ensayo |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
2 regímenes diferentes de tratamiento aleatorizosRandom sequence of two different treatment regimens |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 14 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LPLV Última Visita del Último Paciente |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 10 |
E.8.9.2 | In all countries concerned by the trial days | 0 |